CNS Lymphoma Clinical Trials & Research

MSK has focused on studying central nervous system (CNS) lymphoma for more than 40 years. We are a leader in developing clinical trials for treating this disease.

In the laboratory, we are conducting research to find new treatments for CNS lymphoma. We have collected almost 200 tumor samples and conducted genetic analysis on them. These samples are anonymously linked to clinical data. This helps us make connections between specific genetic changes and the response to particular drugs or overall outcomes.

We are also using these samples to develop models for studying the disease in the lab and to look for new drugs that can be tested in clinical trials. Our research has already revealed information about the changes in cells that cause CNS lymphoma and suggested ways to target those changes.

Learn more about the clinical trials we are currently conducting:

and/or
4 Clinical Trials found
A Phase 1 Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma
Researchers are finding the best dose of MB-CART19.1 immunotherapy in people with lymphoma. The people in this study have central nervous system lymphoma (CNSL) that came back or keeps growing after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1b Study of Epcoritamab and Ibrutinib Given Together in People With Central Nervous System Lymphoma
Researchers want to see if the combination of epcoritamab and ibrutinib is a safe treatment for people with central nervous system lymphoma (CNSL) that keeps growing or came back after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1b/2 Study of Pembrolizumab, Ibrutinib, and Rituximab in People With Primary Central Nervous System Lymphoma
Researchers want to see if combining pembrolizumab, ibrutinib, and rituximab works well against primary central nervous system lymphoma (PCNSL). The people in this study have PCNSL that keeps growing or came back even with treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Lisocabtagene Maraleucel CAR T-Cell Therapy in People With Primary Central Nervous System Lymphoma
Researchers are assessing the cellular therapy lisocabtagene maraleucel (liso-cel) in people with primary central nervous system lymphoma (PCNSL). The people in this study have PCNSL that has not yet been treated. In addition, they cannot have autologous stem cell transplantation (ASCT). During ASCT, a patient's healthy, blood-forming cells are collected before treatment, stored, and returned after treatment with very strong chemotherapy.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau